$65.80
0.550.84%
Last update: Oct 27, 8:29 AM
Celcuity Inc (CELC) Stock Price, Quote, News & History
CELCNASDAQ
Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.
You can purchase shares of Celcuity (NASDAQ:CELC) through any online brokerage.
Other companies in Celcuity’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Celcuity has a consensus price target of $129.31.
The stock price for Celcuity (NASDAQ: CELC) is $66.45 last updated October 27, 2026 at 8:29 AM EDT.
There are no upcoming dividends for Celcuity.
Celcuity does not have any upcoming earnings scheduled.
There is no upcoming split for Celcuity.
Celcuity is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2,...
